New Oral Anticoagulants Should Not Be Used as First-Line Agents to Prevent Thromboembolism in Patients With Atrial Fibrillation-Reference-Cited by-同舟云学术

New Oral Anticoagulants Should Not Be Used as First-Line Agents to Prevent Thromboembolism in Patients With Atrial Fibrillation

Published:2012-01 Issue:1 Volume:125 Page:165-170
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Ansell Jack¹

Affiliation:

1. From the Department of Medicine, Lenox Hill Hospital, New York, NY.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Link

https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.111.031153

Reference46 articles.

1. Studies on the hemorrhagic sweet clover disease, IV: the isolation and crystallization of the hemorrhagic agent;Campbell HA;J Biol Chem,1941

2. Dabigatran versus Warfarin in Patients with Atrial Fibrillation

3. Mahaffey KW Fox KAA on behalf of the ROCKET AF Investigators. Rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. http://sciencenews.myamericanheart.org/pdfs/ROCKET_AF_pslides. Accessed February 23 2011.

4. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

5. Ximelagatran vs Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tailored Approach to Secondary Prevention After Stroke;Ischemic Stroke Therapeutics;2024

2. Research Progress of Left Ventricular Thrombus Formation;Advances in Clinical Medicine;2024

3. Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) do not Increase the Risk of Hepatic Impairment in Patients with Non-Valvular Atrial Fibrillation: Insights from Multi-Source Medical Data;Reviews in Cardiovascular Medicine;2022-03-12

4. Warfarina y anticoagulantes orales directos. Revisión sistemática y metanálisis sobre estudios de no inferioridad en fibrilación auricular y trombosis venosa profunda;Investigación Clínica;2020-03

5. Outcomes of intraparenchymal hemorrhage after direct oral anticoagulant or vitamin K antagonist therapy: A systematic review and meta-analysis;Journal of Clinical Neuroscience;2019-04